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Glossary for systematic reviews and meta-analyses 
Abstract 
A systematic review aims to answer a focussed research question through a structured 
review of the evidence, using a predefined methodology, which often includes a meta-
analysis. A meta-analysis is a statistical method used to combine the effect estimates from the 
individual studies included in a systematic review. Systematic reviews and meta-analyses are 
positioned at the highest level in the hierarchy of clinical evidence. The Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses (PRISMA) statement was introduced in 
2009 to help authors improve the quality and reliability of systematic reviews and meta-
analyses. Recently, the volume of systematic reviews and meta-analyses in the field of 
Endodontology has increased; however, the quality of the published manuscripts has been 
reported to be sub-optimal, which does not take account of the systematic reviews that were 
rejected because of more obvious deficiencies. The aim of this paper is to present a 
comprehensive glossary of terminology commonly used in systematic reviews and meta-
analyses in an attempt to provide easily understood definitions and explanations to assist 
authors when reporting systematic reviews and meta-analyses, and to allow those wishing 
to read them to become better informed.    
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Introduction 
A systematic review is a well-planned and meticulously executed literature review that 
analyses the findings from existing studies to answer a focused research or review question 
(Uman 2011). A meta-analysis, often accompanying a systematic review, is a statistical 
procedure that combines or pools the results of several studies and provides a more accurate 
and precise estimate of the effect of a treatment, intervention or drug, the validity of a 
hypothesis or a risk factor for disease, compared to what an individual study taken in 
isolation is able to achieve (Haidich 2010). Thus, the main aim of a systematic review and 
meta-analysis is to summarise accurately, transparently and reliably the available evidence 
on the efficacy and safety of interventions, techniques or drugs that are used in healthcare 
(Liberati et al. 2009). Ultimately, they aim to provide the most reliable and unbiased resource 
for developing clinical practice guidelines and recommendations for future research and 
clinical practice, whilst also updating individual clinicians and other stakeholders on 
evidence-based care relating to their area of interest (Clarke 2011). In evidence-based clinical 
medicine/dentistry, it is universally accepted that systematic reviews and meta-analyses are 
on the top of the hierarchy of evidence (Burns et al. 2011). 
The number of systematic reviews submitted each year to one journal in the field of 
Endodontology has increased dramatically in recent years, from approximately 19 in 2016 
to 54 in 2018 (Dummer, unpublished data). The quality of systematic reviews and meta-
analyses in Endodontology, published between 2001 and 2009, was reported to be “high” 
(Suebnukarn et al. 2009); however, between 2009 and 2016, it was only categorized as 
“medium” (Kattan et al. 2018). Indeed, Kattan et al. (2018) concluded that although the 
number of systematic reviews and meta-analyses published in Endodontology had increased 
significantly, their quality was judged to have declined to a sub-optimal level. Shortcomings 
in the methodological quality of systematic reviews are of concern, as they are likely to have 
a negative influence on clinical decision-making and have an adverse impact on the progress 
of evidence-based practice in Endodontology (Kattan et al. 2018).  
In view of this trend, and for the benefit of authors, readers and other stakeholders, 
the general methodological and reporting quality of systematic reviews and meta-analyses 
in Endodontology needs to improve (Kattan et al. 2018, Nagendrababu et al. 2018). As part of 
the process, the meaning of key terms used when reporting clinical trials, systematic reviews 
and meta-analyses needs to be clarified. A glossary is a list of terms related to a specific 
subject, field, or area of usage, with accompanying definitions. Defining and explaining 
difficult, discipline-specific or unusual words and expressions used in the text of scientific 
and clinical papers helps reader understanding and has the potential to result in more 
standardized and established terminology for dissemination and implementation within a 
specific field (Rabin et al. 2008).  
There is a wide variety and increasing range of terms used in systematic reviews and 
meta-analyses, which can make it difficult for authors and readers to understand their 
meaning and subsequent use in practice. The aim of this glossary is to provide a 
comprehensive list and brief explanation of the common terms used in systematic reviews 
and meta-analyses. It is designed to highlight the importance and significance of the terms 
and phrases in an attempt to help readers and also allow researchers and authors to use the 
terminology effectively while producing high-quality manuscripts. For each term/phrase, the 
most relevant references have been cited so that readers have the opportunity to engage and 
learn more if they desire.  
 
Commonly used terms in systematic reviews and meta-analyses (in alphabetical 
order) 
1. Allocation concealment – A process to hide information from research participants and 
investigators regarding the sequence of allocation of participants to the intervention 
group(s) in a randomised controlled trial, until the moment of assignment. This is done 
primarily to prevent selection bias by participants and/or investigators who may 
otherwise allocate participants to a preferred/favoured treatment arm (Forder et al. 
2005). 
2. AMSTAR - A MeaSurement Tool to Assess systematic Reviews.  AMSTAR is a reliable 
and valid instrument, which contains 11 items in a checklist that is used to conduct 
and critically appraise systematic reviews (Shea et al. 2007, 2009). The aim of AMSTAR 
is to improve the methodological quality of the reviews for the benefit of authors, 
referees, editors, and readers. 
3. Begg’s test - A test for small-study effects (Item 60), that examines the association of 
standardized treatment effects and their variance using an adjusted rank correlation. 
Similar to Egger’s test (Item 14), when p<0.05 it indicates that a small study effect is 
detected (Begg & Mazumdar 1994, Sterne et al. 2008), hence indicating potential bias 
caused by the influence of small underpowered studies. 
4. Bias - A term used to indicate the deviation of results or inferences from the actual 
truth (Last 1995). Bias can occur at any stage when conducting a study, for example, 
during data collection, data analysis, data interpretation, publication, or review of the 
data, but is generally classified into 3 categories, namely information bias, selection 
bias, and confounding bias. Notably, some authors do not consider confounding bias 
as a type of bias, because is not an error, as it is related to the fact that diseases have 
many causes, some of which are unknown. Bias leads to the lack of validity of the 
results reported in a study (Delgado-Rodriguez & Llorca 2004, Olsen et al. 2010). 
5. Binary outcome - An outcome that has two possible endpoints such as dead/alive, 
occurrence/no occurrence or success/failure. Binary variables are a sub-type of 
dichotomous variables. This type of outcome is usually used in clinical studies, 
including those that are interventional and observational (Petrie & Sabin 2000). For 
instance, the possible endpoint when evaluating the effect of oral premedication on 
the anaesthetic success of inferior alveolar nerve blocks for mandibular molars, while 
performing root canal treatment is the occurrence of pain or no pain.  
6. Cochrane – A leading international organization for evidence synthesis, especially 
systematic reviews and meta-analyses in relation to health 
(https://www.cochranelibrary.com/). The organization is legally registered in the 
United Kingdom. Cochrane’s mission is to promote evidence-informed healthcare 
decision-making by publishing high-quality systematic reviews and other research 
evidence. To date, Cochrane has 11,000 members with over 68,000 supporters from 
>130 countries (Cochrane 2019).  
7. Confidence interval (CI) - A statistical measure for quantifying uncertainty or 
probability around the sample mean. It gives a range of values in which one can be 
confident the true population value will lie within.  The CI is normally used to indicate 
the level of precision associated with an estimate from a sample. In other words, large 
sample sizes usually provide narrow confidence intervals and thus more precision, 
while small sample sizes provide wide confidence intervals and less precision. The CI 
is calculated based on a pre-specified level of significance. If the pre-specified level of 
significance is 95%, we can be 95% confident that the true population value will lie 
with the calculated interval (Ward et al. 2012). For example, a study that determined 
the mean level of blood haemoglobin A1C (HbA1C) in a sample as 7.2 mg%, with its 
corresponding 95% confidence interval as 6.5 mg% to 7.9 mg% means we can be 95% 
confident that the mean of HbA1C in the population (not sample) is within 6.5 mg% to 
7.9 mg%. 
8. Confounding factors – Additional or background factors other than the 
exposure/treatment/intervention that can have an impact on the outcome(s) of a 
treatment or intervention. Confounding factors can lead to spurious results and mask 
the true relationship between the exposure/treatment/intervention of interest and the 
outcome(s) (Skelly et al. 2012). 
9. CONSORT - CONsolidated Standards Of Reporting Trials. The CONSORT statement is a 
minimum set of recommendations for reporting randomised clinical trials that 
comprises a checklist of 25 items and a flow diagram to depict the flow of participants 
through a trial. The use of CONSORT by the authors of trials facilitates complete and 
transparent reporting as well as helping during the critical appraisal and 
interpretation of the results of a trial (Moher et al. 2012). 
10. Continuous outcome - An outcome that has a numeric value on a scale. For instance, 
the outcome of treating patients with a new diabetic medication is haemoglobin A1C 
(HbA1C), which is recorded in numeric values such as 7.5 mg%. However, a continuous 
outcome can be transformed into a binary outcome (Item 5) by grouping it into 
categories, so-called categorical data (Petrie & Sabin 2000). For example, HbA1C that 
is a continuous outcome could be categorized into a binary outcome by defining it as 
<7.0 mg% to indicate the achievement of a treatment goal, while HbA1C≥ 7.0 mg% 
would indicate not achieving the treatment goal. Thus, patients with a HbA1C of 7.5 
mg% would be classified as not achieving the treatment goal.  
11. Direct evidence – A technical term used in a network meta-analysis (Item 33). It 
represents the evidence derived from studies that directly compared one 
intervention with another intervention (Lu & Ades 2004, Lumley 2002). For example, 
a network meta-analysis that compared interventions A, B, and C could include 
several randomised controlled trials that revealed comparative evidence of 
intervention A versus B and intervention A versus C. However, no study compared 
intervention B versus C. Thus, there was direct evidence of intervention A versus B 
and direct evidence of intervention A versus C, but no direct evidence of intervention 
B versus C.  
12. Drop-outs – The attrition or loss of subjects in one or more arms of a trial, sometimes 
called, non-participation. Drop-outs can occur for a variety of reasons including the 
effects of the drug/intervention, the unavailability of participants for review or their 
refusal to take a further part in the trial. If the number of drop-outs is substantial it 
can affect the validity of the results and the conclusions (Bell et al. 2013). It is 
imperative that the number and reason for subjects dropping-out are reported in 
detail within a trial. 
13. Effect size – The magnitude of difference between groups, when two or more 
interventions are being compared; it is also called the treatment effect or effect 
estimate. For continuous outcomes (Item 10), the effect size is the difference between 
the mean value of the intervention and comparator, also called the mean difference. 
However, in some situations within a meta-analysis where studies were conducted 
using different measurements or scales, the mean difference cannot be used for 
pooling the effect size. Therefore, the standardised mean difference (Item 61) is used 
to transform the effect to a scale that is easily understood. For binary outcomes (or 
categorical outcomes), the effect size can be presented using the odds ratio, risk ratio, 
rate ratio, hazard ratio, or other measures (Sullivan & Feinn 2012).   
14. Egger’s test - Is a test for small study effects (Item 60). It examines whether the 
association of treatment effects and their variance is greater than that expected by 
chance. Egger’s test uses the linear regression approach by associating the treatment 
effect estimate against its standard error weighted by the inverse variance of the 
treatment effect (Egger et al. 1997, 2008). P<0.10 indicates that the association of 
treatment effects and their variance is greater than chance, which means that a small 
study effect has been detected. See Begg’s test (Item 3). 
15. Eligibility criteria - Specific conditions that define the criteria for the 
inclusion/exclusion of studies in a systematic review in order to answer the research 
question (Item 53). These criteria are framed on the basis of the population, 
intervention (or exposure), control, outcome and study design (PICOS) in a systematic 
review. Adherence to the eligibility criteria prevents bias in the selection of studies, 
which is generally not observed in a narrative review (Higgins & Green 2011, McCrae 
et al. 2015). 
16. Evidence gap map – A tool for collecting and summarising existing evidence to inform 
policy decision-making and to prioritize future research. It maps out existing and 
ongoing primary studies or systematic reviews in a particular sector or subsector in 
terms of the types of policies or programmes evaluated and the outcomes measured. 
It is usually presented as a visualized map and highlights the gaps where no (or little) 
evidence exists (International Initiative for Impact Evaluation [3ie] 2019). 
17. Fixed-effect model – A statistical method for combining the findings from the included 
studies. It uses a principle of weighted average to combine the findings across studies 
using the effect size and variance of each study. However, a fixed-effect model is valid 
only under the assumption that all effect sizes are estimating the same underlying 
intervention effect (Deeks et al. 2008). 
18. Forest plot – Provides a graphic summary of the size of the overall effect of all the 
included studies from a meta-analysis within a systematic review. The weighted effect 
sizes and statistical heterogeneity are displayed as a plot with the summary effect size 
depicted as a diamond figure within the plot.  
 
Figure 1 illustrates a forest plot of a hypothetical meta-analysis using random-
effects modelling to evaluate the efficacy of intracanal medicaments to prevent the 
recurrence of apical periodontitis compared to a control (without intracanal 
medicament) that gives the summary estimates as risk ratio (RR) with 95% confidence 
interval (CI). Five studies are illustrated in the plot. The x-axis forms the effect size 
scale. In each row (horizontal lines), the treatment effect for the individual study is 
represented by a blue square with the horizontal line representing the corresponding 
95% confidence interval (CI). The size of the blue square is proportional to the 
percentage weight, which is an indication of the influence each study had on the 
pooled result of the meta-analysis. Therefore, the larger the square the more “weight” 
the study has in the meta-analysis. The weight (in %, provided in the right-hand column 
of Figure 1) is the percentage weight given to the study in the pooled meta-analysis. 
The general rule is that the larger the study in terms of sample size, the greater the 
percentage of weight (influence) given to that study. The vertical line in the middle of 
the plot is where the intervention and the placebo have had the same effect on 
recurrence of apical periodontitis. In other words, there is no difference in the 
recurrence of apical periodontitis with and without an intracanal medicament. This 
line is called the “line of no effect”. If the horizontal line in each row touches or crosses 
the line of no effect, it means that the trial found no significant difference between the 
two treatments (intervention and control). Among the five studies, only one study (AC, 
2014) does not touch the line of no effect, which means for that study alone there is a 
significant difference in the recurrence of apical periodontitis between the 
intervention and control group.  The bottom row (or “summary row” or “overall”) in 
Figure1 represents the result of the meta-analysis. The red diamond along the bottom 
row represents the pooled quantitative result from the meta-analysis. The dotted 
vertical line running along the middle of the diamond is the result of the pooled meta-
analysis for the treatment effect, and the horizontal width of the diamond is the 
certainty of the result, again usually presented as a 95% confidence interval. As in this 
example, if the CI does not cross the line of no effect, then there is a significant 
difference between the effectiveness of the intervention and control group.  
 
Interpretation of the results: If the RR is 1 (or the 95% CI includes the value 1), it 
suggests no difference or little difference in risk (i.e. the incidence in each group is the 
same); A RR > 1 (and the 95% CI does not include the value 1) suggests an increased 
risk of that outcome in the intervention group; A RR < 1 (and the 95% CI does not 
include the value 1) suggests a reduced risk in the intervention group. According to 
the summary estimates in Figure 1, RR is 0.75 and the 95% CI does not include the 
value 1 (0.58 to 0.96), that is, in relation to the 95% confidence interval the p-value is 
<0.05, that is, it is significant. At the same time, the position of the red diamond 
favours the intervention as it does not touch or cross the line of no effect. In traditional 
terminology, this means that the meta-analytic effect is statistically significant. The 
corresponding Z-value and p-value (one-tailed and two-tailed) are also provided below 
the Forest plot. The corresponding p-value is <0.05 and also indicates statistical 
significance. Hence the pooled quantitative result of the meta-analysis is statistically 
significant and a reduced risk of reoccurrence for apical periodontitis is expected 
from the intervention group (with intracanal medicament) compared to the control 
group (without intracanal medicament). In other words, the intervention reduced the 
risk of apical periodontitis by 25% (% risk reduction= (1-RR) x 100 = (1-0.75) x 100 =25%). 
Heterogeneity (I2) (Item 23) is expressed as a percentage with a range between 0 and 
100. In the example, I2 is 0% with p>0.05, suggesting there is no study heterogeneity.  
 
Figure 2 is a forest plot that summarises the efficacy of intracanal 
medicaments to prevent the recurrence of apical periodontitis compared with 
controls (without intracanal medicament). The overall summary estimate states that 
RR is 0.91 and the 95% CI includes the value 1 (0.73 to 1.13). At the same time, the red 
diamond touches the line of no effect, which in traditional terminology, means that 
the meta-analytic effect is not statistically significant. Therefore, overall, no difference 
occurred between the intervention (with intracanal medicament) and control (without 
intracanal medicament).  
 
In Figure 3, the overall summary estimates, RR is 1.81 and the 95% CI does not 
include the value 1 (1.37 to 2.39). At the same time, the position of the red diamond 
favours the control group as it does not touch or cross the line of no effect. This shows 
that the meta-analytic effect is statistically significant. The inference is that those who 
were exposed the intervention had an 81% (% increase= (RR-1) x 100 = (1.81-1) x 100 = 
81%) increased risk of reoccurrence of apical periodontitis compared to the control. In 
other words, the intervention increased significantly the risk of apical periodontitis 
compared with the control.  
19. Funnel plot - Provides an indication of publication bias (Item 46) or small-study effects 
(Item 60) that could affect the validity of the results of a meta-analysis. By plotting the 
standard error of the effect size on a reversed scale on the y-axis, those studies with 
large sample sizes are placed at the top of the graph with smaller studies scattered on 
the lower part of the plot. The plot is bounded by a triangle formed from the summary 
measure with 95% confidence interval estimated from the fixed-effect meta-analysis. 
This triangle will include 95% of the studies when publication bias is absent. The 
symmetry of the smaller studies on both sides of the plot or clustering of larger 
studies on the top also indicates no / low possibility of publication bias (Sterne et al. 
2011). Figure 4 is a funnel plot with 15 studies (15 dots). It is close to symmetrical and 
confirms that the smaller studies were distributed relatively symmetrically. 
20. Generalizability - The ability, based on a researcher’s opinion, to decide to what extent 
the findings of a study can be extrapolated from the sample to an entire population. It 
has typically been discussed as one aspect of external validity (Flick 2018). 
21. GRADE - Grading of Recommendations, Assessment, Development and Evaluations. 
GRADE is a framework that evaluates the quality, certainty, and level of evidence for 
developing clinical practice recommendations (Guyatt et al. 2008). The evaluation is 
based on the risk of bias (risks of systematic errors) (Item 54), imprecision (risks of 
random errors) (Item 24), inconsistency (Item 25), indirectness (Item 27), and 
publication bias (Item 46).  
22. Grey literature - Literature that is not formally published in sources such as books or 
journals, but includes academic papers, dissertations, research and committee 
reports, government reports, newspaper, conference abstracts, and ongoing research 
(Paez 2017). Examples of databases for grey literature are OpenGrey 
(www.opengrey.com), New York Academy of Medicine Grey Literature Report 
(http://www.greylit.org/), Bielefeld Academic Search Engine (BASE) (https://www.base-
search.net/). Grey literature is unpublished work or work published in a non-
commercial manner. 
23. Heterogeneity - Is a measure of variability among included studies in a systematic 
review. Diversity among studies included in a systematic review is common, at least 
in terms of clinical and/or methodological perspectives. Therefore, this effect needs to 
be assessed and considered when the meta-analysis is performed, in order to estimate 
the pooled effect from a set of similar studies. Determining statistical heterogeneity 
can be achieved using a chi-squared test.  A low P-value (usually lower than 0.10) or a 
large chi-squared statistic relative to its degree of freedom, highlights evidence of 
heterogeneity associated with the effects of an intervention. Another method is to 
look at the I2 value which can be derived from the Q statistic (Cochran’s Q). According 
to Cochrane handbook. I2 of 0% - 40% suggests low heterogeneity that is not 
important, 30% - 60% indicates moderate heterogeneity, 50% - 90% indicates 
substantial heterogeneity, while 75% - 100% indicates considerable heterogeneity 
(Deeks et al. 2019).   
24. Imprecision - Is one of the criteria for grading the quality of evidence developed by the 
GRADE (Item 21) working group. The overall criteria consist of the risk of bias, 
publication bias, imprecision, inconsistency, and indirectness. Imprecision focuses on 
the variability around the treatment effect measured by a CI. It represents the 
confidence of reviewers in the observed treatment effect. A wider CI indicates higher 
imprecision, while a narrower CI indicates lower imprecision.  (Guyatt et al. 2011a). 
25. Inconsistency – Confidence in a body of evidence is increased when there are a large 
number of studies that demonstrate the same consistent effects.  Inconsistency means 
that there is an unexplained heterogeneity in the findings from a meta-analysis. If 
there is important unexplained heterogeneity in the findings, the confidence in the 
estimate of the effect for that outcome decreases. The degree of inconsistency could 
be assessed through the similarity of point estimates between direct evidence and 
indirect evidence, the overlap of their CIs, and heterogeneity among studies.  
26. Indirect evidence – A technical term used in a network meta-analysis (Item 33) that 
indicates the evidence generated by a network meta-analysis through a common 
comparator (Lumley 2002, Lu & Ades 2004). For example, a network meta-analysis 
comparing interventions A, B, and C. Several randomised controlled trials revealed 
comparative evidence of intervention A versus B and intervention A versus C. 
However, no study was conducted to compare intervention B versus C. Indirect 
evidence of intervention B versus C can be estimated through the association of 
intervention A versus B and intervention A versus C using intervention A as the 
common comparator.  
27. Indirectness – Is one of the criteria for grading the quality of evidence developed by 
the GRADE (Item 21) working group. The overall criteria include risk of bias, 
publication bias, imprecision, inconsistency, and indirectness. Indirectness focuses on 
the existence of research that directly compares the interventions of interest in the 
population with important outcomes for patients. Evidence with high indirectness 
means the population, interventions, and outcomes of research under consideration, 
differ from those in which we are interested. In addition, evidence with substantial 
indirectness occurs when there are no head-to-head or direct comparisons between 
the interventions of interest (Guyatt et al. 2011b). 
28. Intention-to-treat analysis – An analytical approach that aims to compare outcomes 
based on a group of patients allocated after randomisation, even though they may not 
have fully complied with the indicated treatment as the study progressed (e.g. a 
patient who was not taken their medication for the duration of the study, patient who 
dropped-out, etc.). The results obtained from an intention-to-treat analysis will 
estimate what happens in the “real world”, where the situation is not perfect. This 
approach is commonly used when assessing the results of clinical trials, preferably 
when analysing a superiority trial (Higgins et al. 2019).   
29. Meta-analysis – A statistical technique that pools the findings, results or data of several 
independent studies included in a systematic review (Haidich 2010). A meta-analysis 
mimics the conduct of a larger study by combining the data from several individual 
studies included a systematic review and, as a consequence, provides more precise 
summary estimates (Moher et al. 2015). In health sciences, meta-analyses are cited 
more often than other study designs (Patsopoulos et al. 2005).  
30. Meta-regression – Meta-regression is a statistical method to investigate heterogeneity 
(Item 23) within a meta-analysis. It allows the meta-analyst to investigate the effect of 
potential effect modifiers on the pooled effect estimates, whether the potential effect 
modifiers are continuous or categorical variables. Meta-regression is similar to a 
simple regression. The treatment effect is the outcome variable, while study’ 
characteristics are considered as explanatory variables that might affect the 
treatment effect.  However, there are two differences between a meta-regression and 
a simple regression. Firstly, a meta-regression considers the sample size of each study 
within its analysis. Studies with large sample sizes have more influence on the 
relationship between the outcome variable and explanatory variables than studies 
with a small sample sizes because studies are weighted by the variation of their 
treatment effect. Secondly, a meta-regression does not consider heterogeneity among 
treatment effects within its analysis. However, a meta-regression should not be 
considered when the number of included studies is fewer than 10 because the 
statistical power is insufficient to detect significant differences (Deeks et al. 2008, 
Harbord & Higgins 2016). 
31. Mixed treatment comparison - Mixed treatment comparison is an infrequently used 
term used interchangeably with a network meta-analysis.  Multiple treatment meta-
analysis has a similar meaning (Chaimani et al. 2019). 
32. Narrative review – A traditional literature review designed to (critically) describe and 
discuss the information available from books and journals on a specific topic from a 
theoretical and contextual point of view. Although the norm in science, narrative 
reviews are not particularly useful in clinical research as they are not reproducible, 
often biased, nor do they answer a specific quantitative research questions as they do 
not follow a strict methodological approach such as using inclusion/exclusion criteria, 
specific literature databases, search processes, nor use a quality assessment tool to 
evaluate the included studies. 
33. Network meta-analysis – Compares multiple interventions (more than two) by 
evaluating and analysing direct and indirect comparisons among trials. Direct 
comparison is similar to a conventional pair-wise comparison when studies 
comparing interventions are available. Indirect comparisons are undertaken against 
a common comparator (usually placebo or an existing gold standard intervention). A 
network meta-analysis ranks the various interventions from the most to least 
effective. The basic concept behind a network meta-analysis is as follows: consider 
three individuals, X, Y and Z. If Y is 7 kg heavier than X, and Z is 10 kg heavier than X, 
then we know that Z is 3 kg heavier than Y, and is therefore the heaviest of the three. 
The individuals can also be ranked in terms of who is heaviest as 1st =Z, 2nd =Y and 
3rd =X. So, by taking the weight of individual X as a reference and measuring the 
weights of the others compared with theirs, the weight of everyone can be compared 
and how they are ranked (in order) by their individual weight can be deduced.  
34. Network plot - Plots a network of interventions as a visual presentation of the 
evidence-base and offers a concise explanation about its characteristics. Figure 5 is a 
network plot of a hypothetical situation, which aimed to find the answer for the 
research question: what is the most effective oral medication in reducing post-
operative pain in adults following root canal treatment? For example, in the 
endodontic literature, three drugs (A, B and C) have been studied. However, so far, no 
clinical trials have been conducted to compare the effectiveness of drug C with drugs 
B and A. In this situation, a network meta-analysis compares the effectiveness of drugs 
A, B and C by evaluating and analysing direct and indirect comparisons among trials 
to find the answer for the research question above. The network plot consists of nodes 
representing the interventions being compared. In Figure 5, four interventions 
(nodes) shown as coloured circles were compared including a placebo, while the lines 
connecting the nodes represent the existing direct evidence which means there is at 
least one study comparing the effect of that pair of interventions (also called contrast). 
The size of each node usually represents the sample size within the intervention with 
larger nodes indicating larger sample sizes. The thickness of the line represents the 
number of studies comparing the pairs of interventions with thicker lines indicating 
larger numbers of studies.  
The edge thickness (the connecting line between two interventions) is proportional to 
the number of studies comparing the two interventions, thus illustrating which 
interventions were more frequently compared. In Figure 5, the line between B and the 
placebo is thicker, which means more clinical trials had been conducted between 
these two interventions. On Figure 6, there is direct evidence available (line) for 
studies comparing A versus placebo, B versus placebo, and A versus B. However, no 
direct evidence (line missing) is available for C versus B and C versus A. In the absence 
of direct comparison among interventions, a network meta-analysis synthesizes both 
direct and indirect evidence in a network of trials that compares the numerous 
interventions and has the ability to rank the drugs. 
35. Odds ratio – Is the ratio between the odds of exposure to a factor among people with 
a condition or disease (cases) and the odds of exposure to a factor among those who 
do not have the condition or disease (controls). This ratio is a statistic that quantifies 
and represents the strength of the association between an exposure and a disease in 
a case-control study. For interpretation, the odds of exposure in the two groups is the 
same if the odds ratio is equal to 1. The odds of exposure are considered to be lower 
or greater in the diseased group if the ratio is less than 1 or more than 1, respectively 
(Bonita et al. 2006). 
36. Outcome - The effect of a treatment or drug or technique that can be measured reliably. 
Within randomised clinical trials there are generally primary and secondary 
outcomes.  Examples: postoperative pain assessed using a visual analogue scale or 
periapical healing assessed using standardised periapical radiographs.  
37. Per-protocol analysis – A comparison of interventions that includes only those 
participants who completed the treatment they were originally allocated. Example: a 
randomised clinical trial designed to compare the effect of a newly developed irrigant 
with chlorhexidine on the outcome of root canal treatment after 24 months. If some 
participants drop-out of the clinical trial before examiners measured the outcome, a 
per-protocol analysis would not combine their results with those participants who 
completed treatment. In non-inferiority trials, both intention-to-treat (item 28) and 
per-protocol analysis are recommended; both approaches should support non-
inferiority. 
38. PICOS format - A structured approach for developing research questions within a 
systematic review that includes five components. The acronym ‘‘PICOS’’ where each 
letter stands for: the patient population or the disease being addressed (P), the 
interventions or exposure (I), the comparator (C), the outcome or endpoint (O), and the 
study design chosen (S). Example: Does mineral trioxide aggregate (I) compared to 
formocresol (C), result in better clinical success (O) in primary molar teeth undergoing 
pulpotomy (P) in randomised clinical trials (S)? 
39. Power - From a statistical perspective, power is the probability of rejecting the null 
hypothesis when the null hypothesis is false (correct decision). To simplify, power is 
the probability of detecting a statistically significant difference when two 
interventions are truly different. However, there might be a chance that two 
interventions are deemed not to be different when they are actually truly different 
(called Type II error). Thus, statistical power is not 100% perfect. In the medical 
literature, a statistical power of 80% or more is accepted as sufficient, which means 
that the acceptable level of probability to make a correct decision should be at least 
80% or a 20% error is accepted to determine that two interventions are not different 
even though they are different (Petrie & Sabin 2000). 
40. Precision - The effect estimate from a particular study may carry a degree of 
uncertainty and less power to detect a significant result. Therefore, by using a meta-
analysis the pooled effect estimates from similar studies can improve the precision of 
the treatment effect, which can be determined by the confidence intervals. Wider 
intervals indicate greater uncertainty (less precision). However, there is no exact value 
to determine whether the precision is too low. Readers need to make a judgement to 
consider whether the interval is too wide for the degree of precision (Schünemann et 
al. 2019). 
41. PRISMA – Preferred Reporting for Systematic Reviews and Meta-Analyses 
(http://www.prisma-statement.org/). PRISMA provides a minimum set of items that are 
required to ensure the quality of reports describing systematic reviews and meta-
analyses.  It consists of a checklist with 27-items and one four-phase flow diagram 
(Liberati et al. 2009). PRISMA is recommended by numerous journals in the medical 
and dental fields.  
42. PRISMA-P – Are guidelines to facilitate the development of a protocol prior to carrying 
out a systematic review. The protocol a priori reports on the purpose and 
methodology of the systematic review, which avoids any bias that could occur during 
its conduct. PRIMSA-P was developed from items within the PRISMA checklist and 
PROSPERO register (Moher et al. 2015). 
43. PROSPERO – An international database of prospectively registered systematic 
reviews. It is a free online portal that facilitates the publication of the protocol of 
systematic reviews related to health. The primary aim is to document a priori 
protocols, avoid duplication of reviews at the developmental stage, provide 
transparency in the conduct of reviews and aid in the evaluation of reporting bias 
(Moher et al. 2015).  
44. Protocol - A protocol of a systematic review and meta-analysis should be established a 
priori to describe the purpose, research question and methods of the systematic 
review in advance of it being conducted. Protocols should be published (e.g. Cochrane 
(Item 6), PROSPERO (Item 43) and made available before, during and after a 
systematic review is carried out. Protocols of reviews should contain a rationale, a 
priori methodology, quality assessment and the statistical approach to be adopted 
during the review (Moher et al. 2015). 
45. P-score - A statistical method used to rank treatment hierarchy in a network meta-
analysis, based on a frequentist approach (a method to undertake a network meta-
analysis). This value is derived from the frequentist point estimate and its standard 
error. P-scores can be considered as equivalent to a SUCRA value (Item 63), which both 
allow treatments to be ranked on a continuous 0-1 scale (Rucker & Schwarze 2015).  
46. Publication bias – A form of reporting bias resulting from the preferred publication of 
papers with positive or acceptable results. This can lead to negative results being 
under-represented in the published literature and subsequent systematic reviews. A 
systematic search leads to the selection of all results, positive or negative, and should 
be reflected in the results of a systematic review. Publication bias can be evaluated 
through a funnel plot (Item 19). 
47. Quasi-randomized controlled trials – In this study design, the participants are allocated 
to different arms of the trial (to receive the intervention or placebo) using a method of 
allocation that is not truly randomised. In quasi-randomisation there is a greater 
chance of risk that the investigator will be aware of which participant is in which 
group, in other words, the risk of selection bias will be introduced. 
48. Random effects model - A meta-analysis approach that incorporates an assumption 
that the various included studies are estimating the effects of different interventions 
(Deeks et al. 2019). Opposite to fixed-effect model, a random effects model assumes 
that studies included in a meta-analysis are from a random sample of existing studies 
and the observed treatment effect is the average of the true treatment effects within 
a relevant distribution. The random effects model will give a similar result to a fixed-
effect model when heterogeneity among the studies is not observed. 
49. Randomisation – A mandatory step in a randomised clinical trial that provides an equal 
chance that all selected participants can be allocated to the available intervention 
groups. It is an accepted method to avoid selection bias. Various types of 
randomisation methodology can be used in studies, including simple, stratified and 
block techniques. 
50. Randomised clinical trial – A prospective experiment (usually medical or health-
related) that compares the effectiveness of two or more interventions/treatments. 
Normally, the test intervention being evaluated is compared against a standard 
treatment (gold standard) or no treatment (placebo). 
51. Rankogram - Is a graphical tool to present the possible ranking of each intervention 
among all the comparisons in the network meta-analysis 
(https://methods.cochrane.org/cmi/glossary). This two-dimensional graph is plotted 
between the probability for each intervention to have a specific rank in the vertical 
axis and the number of possible ranks in the horizontal axis (Chaimani et al. 2013, 
Salanti et al. 2011). 
52. Realist review - This type of qualitative review also uses a systematic review approach, 
but is designed to review whether social or policy interventions work (or not) in a ‘real 
world’ or in a practical sense. It aims to provide an explanatory analysis of how and 
why they work in particular ‘real world’ contexts or settings. Not tasked with 
necessarily establishing the most academic-based solution, rather a realist review 
aims to answer “what works for whom in what circumstances, in what respects and 
how?”, with respect to community intervention programs (Pawson et al. 2005).  The 
literature included in realist reviews should focus on real-world studies and 
pragmatic trials. These patterns predict which aspects of the intervention make it 
pragmatically effective, and which are required to replicate that success across a 
range of contexts (Gwyther et al. 2018) 
53. Research question – A well-formulated research question will guide many aspects of 
the review process, such as inclusion/exclusion criteria, searching for studies, data 
collection from included studies, and presenting the findings. The research question 
should be clear and focused - not vague, too specific or too broad. The review question 
should specify the types of population (participants), types of interventions with 
comparisons and the types of outcomes that are of interest. The acronym PICOS helps 
to serve as a reminder of these. Good research questions may have a narrow or broad 
focus, depending on the overall objectives of the review. 
54. Risk of bias tool - A tool for assessing the risk of bias in studies included in systematic 
reviews. Briefly, the biases which might occur in studies consist of selection bias, 
performance bias, attrition bias, detection bias, and reporting bias. The tool is used to 
assess those biases within studies. Several versions of the tool have been introduced 
based on the design of the original studies included in a systematic review such as 
risk of bias tool for randomised controlled trials of intervention (ROB tool) (Higgins et 
al. 2008, Sterne et al. 2016), risk of bias tool for non-randomised studies of 
intervention (ROBINS-I tool) (Sterne et al. 2016), risk of bias tool for systematic review 
(ROBIS tool) (Whiting et al. 2016), and risk of bias tool for animal studies (SYRCLE tool) 
(Hooijmans et al. 2014).     
55. Risk ratio - Is the ratio of the risk of occurrence of a disease among exposed individuals 
to that among unexposed individuals. It is used when assessing the likelihood that an 
association represents a causal relationship. The interpretation of risk ratio is similar 
to the interpretation of an odds ratio (Item 35) but should be considered as “risk” 
instead of “odds” (Bonita & Kjellström 2006). 
56. Scoping review - To determine the scope or coverage of a body of literature on a given 
topic and provide clear indication of the volume of the literature and studies available 
as well as an overview of its focus. A scoping review provides an overview of a 
potentially large and diverse body of literature related to a broad topic without 
critically appraising individual studies, whereas systematic reviews combine 
empirical evidence from a relatively small number of studies associated with a 
focused review/research question and assesses the quality of the included studies 
(Colquhoun et al. 2014, Munn et al. 2018). 
57. Search strategy – Used a priori to search, identify and select the appropriate and 
relevant evidence to answer the research question of a systematic review. Search 
terms are identified and arranged to retrieve eligible studies and information from 
electronic databases, websites and reference lists of the included studies, and 
previously published reviews.  
58. Selective outcome reporting bias – The bias due to the selection of a subset of outcomes 
among recorded outcomes to be reported (Hutton 2000). The selective outcome 
reporting of some outcomes but not others, depending on the nature and direction of 
the results. For example, reporting bias can occur due to the tendency for journals to 
publish only positive results. 
59. Sensitivity analysis - An analysis of the main outcome scrutinised under alternative 
assumptions to determine the robustness or stability of the observed outcomes, such 
as analysis with the exclusion of studies with a high risk of bias, studies with small 
sample size, or of poor quality. This analysis is useful for synthesising the evidence 
according to the observed results (Chaimani et al. 2019, Deeks et al. 2019). 
60. Small-study effects - The phenomenon that occurs when smaller studies occasionally 
are associated with different, often larger, treatment effects than large studies, which 
may indicate publication bias. This effect may be evident when studies with small 
sample sizes are more likely to be published if the finding are positive. Determining if 
there is evidence of small-study effects can be achieved using several methods, such 
as inspection of the funnel plots, Egger’s test (Chaimani et al. 2017, Debray et al. 2018). 
61. Standardized mean difference – Is used as a summary statistic in a meta-analysis when 
the included studies report the same outcomes using different measurements or 
different scales. For example, studies reported the effect of an intervention of pain 
reduction may use a visual analogue scale with a scale of 0-10, while others may use 
a visual analogue scale with a scale of 0-100. A meta-analysis could not combine the 
findings using their original treatment effect. Thus, standardized mean difference 
(SMD) is an option for combining the findings of studies’. SMD is calculated by using 
the mean difference between groups divided by its standard deviation. Notably, SMD 
should not be directly interpreted as a simple mean difference because SMD is 
reported in a unit of standard deviation. A simple way to interpret the SMD is that 0.2 
represents a small effect, 0.5 a moderate effect, and 0.8 a large effect.  
62. Subgroup analysis - An analysis to investigate whether the observed effect of an 
intervention is consistent across well-defined types of participant. It is generally 
performed to determine the effect between the particular patient group, types of 
intervention, or types of study. However, subgroup analyses of subsets of participants 
within studies are sometimes impossible to perform in systematic reviews because of 
insufficient details within the published literature that prevent the data being 
extracted (Deeks et al. 2019, Tierney et al. 2019).  
63. SUCRA - The “Surface Under the Cumulative RAnking” curve or SUCRA is the area 
under the curve of cumulative rankograms. SUCRA is usually presented in terms of 
numbers ranging between 0 and 1, but can be reported as a percentage. For 
interpretation, the larger the SUCRA number, the better is the position within the 
treatment hierarchy according to the outcome 
(https://methods.cochrane.org/cmi/glossary).  
64. Summary measures – A measure of treatment effect used to report the results of a 
meta-analysis. In general, the treatment effect can be presented as a summary 
measure in terms of odds ratio, rate ratio, or relative risk for a dichotomous variable 
or mean difference for a continuous variable. 
65. Systematic review – Locates and reviews all the relevant literature that fits pre-
specified inclusion/exclusion criteria to answer a specific research question. It uses a 
clear and systematic methodology to reduce bias in the identification, selection, 
synthesis, and summary of studies. It provides reliable findings from which 
conclusions can be used to inform clinical decision making (Moher et al. 2015).  
66. Trial sequential analysis (TSA) - Calculates the required information size (RIS) for a 
meta-analysis similar to a sample size calculation for a clinical trial. TSA can evaluate 
the effect of random error, false positive, and false negative values on the results of a 
meta-analysis. The RIS that is calculated can be used to monitor the sufficiency of 
studies to provide a valid and reliable result when an update of a meta-analysis is 
undertaken.  
 
Figure 6 compares the effectiveness of intracanal medicaments to prevent the 
recurrence of apical periodontitis compared with controls (without intracanal 
medicament). TSA were calculated with type 1 error of 5% and type II error of 20% and 
a required information size (n= 4560) based on the intervention effect suggested by 
the included trials using a random-effects model for intervention (RRR of 25% (as per 
meta-analysis provided in Figure 1, the pooled risk ratio is 0.75. hence, risk reduction 
(RRR in %) is 25% (1-RR) and control group event proportion of 8.87% (Figure 1, 
(number of patients exposed to events in control group (119)/total number of patients 
in control group (1284)). The number of patients included in the meta-analysis 
(n=2954) did not exceed the required information size (red dotted vertical line) and the 
cumulative z-curve (blue line) did not cross the trial sequential boundary (red-dotted 
curve), which indicates that the evidence demonstrated by the meta-analysis in Figure 
1 is not conclusive.  
Figure 7 compares the effectiveness of intracanal medicaments to prevent the 
recurrence of apical periodontitis compared to controls (without intracanal 
medicament). TSA were calculated with type 1 error of 5% and type II error of 20% and 
a required information size (n= 3730) based on the intervention effect suggested by 
the included trials using a random-effects model for intervention (RRR of 27%) and 
control group event proportion (number of patients exposed to events in control 
group (117)/total number of patients in control group (1284)) of 9.1% (Supplementary 
Figure 1). Although the number of patients included in the meta-analysis did not 
exceed the required information size, the cumulative evidence is conclusive for a 27% 
reduction of risk for reoccurrence of apical periodontitis because the cumulative z-
curve has crossed the trial sequential boundary. This indicates that the evidence 
demonstrated by the meta-analysis (Supplementary Figure 1) is conclusive. 
67. Umbrella review - Provides the highest levels of evidence as they combine the results 
of published systematic reviews or/and meta-analyses (Fusar-Poli & Radua 2018). An 
umbrella review is able to demonstrate whether the evidence-base around a topic or 
question is consistent or whether it is contradictory or whether discrepant findings 
exist, and if they do, explores and details the reasons why. Umbrella reviews allow 
assessment and consideration of whether each included systematic review addressed 
similar research or review questions, observed similar results independently and 
arrived at similar conclusions.  This form of review is a summary syntheses of the 
evidence that exists (Aromataris et al. 2015). 
68. Weighted mean difference - Weighted mean difference (WMD), or “mean difference”, or 
“difference in means” is a standard statistic when a meta-analysis is performed to 
determine the pooled effects of continuous variables. The absolute difference will be 
computed between the mean values of the intervention and control group. The weight 
given to each study is determined by the precision of its estimate of effect. If the 
outcome measurements from all of the studies are made on a similar scale, then the 
weighted mean difference can be used as a summary statistic in the meta-analysis 
(Higgins et al. 2019).  
 
Conclusion 
This article provides a comprehensive glossary, which contains definitions and explanations 
for the most commonly used terms employed when conducting and reporting systematic 
reviews. These terms will benefit authors when planning and producing high quality 
systematic reviews and meta-analysis in Endodontology. High quality systematic reviews 
and meta-analyses will minimize the possibility that their results or findings are influenced 
by bias, which provides confidence to clinicians when applying them in their day-to-day 
clinical practice. 
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Legends 
Figure 1: Forest plot evaluating the efficacy of intracanal medicaments to prevent the 
reoccurrence of apical periodontitis compared to controls (without intracanal medicament) 
revealing a significant difference between the groups with and without an intracanal 
medicament in favour of medicaments. 
Figure 2: Forest plot evaluating the efficacy of intracanal medicaments to prevent the 
reoccurrence of apical periodontitis compared to controls (without intracanal medicament) 
revealing no significant difference between the groups with and without an intracanal 
medicament.  
Figure 3: Forest plot evaluating the efficacy of intracanal medicaments to prevent the 
reoccurrence of apical periodontitis compared to controls (without intracanal medicament) 
revealing a significant difference between the groups in favour of the control. Thus, the 
intervention increased significantly the risk of apical periodontitis occurring compared to 
the control.  
Figure 4: Funnel Plot showing that smaller studies (smaller dots) were distributed relatively 
symmetrically. (RR – relative risk) 
Figure 5: Network plot comparing the effectiveness of three drugs (A, B, C) for reducing 
postoperative pain following root canal treatment and the demonstrated relationship 
between them and the placebo.    
Figure 6: Trial sequential analysis comparing the effectiveness of intracanal medicaments 
to prevent the recurrence of apical periodontitis compared with controls (without intracanal 
medicament). The number of patients included in the meta-analysis (n=2954) did not exceed 
the required information size (red dotted vertical line on the extreme right) and the 
cumulative z-curve (blue line) did not cross the trial sequential boundary (red-dotted curve 
on the upper half of the diagram), which indicates that the evidence derived from the meta-
analysis (Figure 1) was not conclusive.  
Figure 7: Trial sequential analysis comparing the effectiveness of intracanal medicaments 
to prevent the recurrence of apical periodontitis compared with controls (without intracanal 
medicament). The number of patients included in the meta-analysis (n=2954) did not exceed 
the required information size (red dotted vertical line on the extreme right).  However, the 
cumulative z-curve (blue line) has crossed the trial sequential boundary (red-dotted curve 
in upper half of diagram). This demonstrates that the cumulative evidence obtained by the 
meta-analysis (Supplementary Figure 1) is conclusive for a 27% reduction of risk for 
reoccurrence of apical periodontitis. 
 
Supplementary Figure 1: Forest plot evaluating the efficacy of intracanal medicaments to 
prevent the reoccurrence of apical periodontitis compared with controls (without intracanal 
medicament). The summary estimates, RR is 0.73 and the 95% CI does not include the value 
1 (0.57 to 0.93). At the same time, the position of the diamond favours the intervention group 
as it does not touch or cross the line of no effect, which means the meta-analytic effect is 
statistically significant. The inference is that those who were exposed the intervention had a 
27% (% decrease= (1-RR) x 100 = (1-0.73) x 100 = 27%) reduced risk of reoccurrence of 
apical periodontitis compared to the control.  
 
 
Figure 1 
 
Figure 2  
 
Figure 3  
Figure 4 
 
Figure 5 
  
 
Figure 6 
 
Figure 7
Supplementary Figure 1: Forest plot evaluating the efficacy of intracanal medicaments to prevent the 
reoccurrence of apical periodontitis compared with controls (without intracanal medicament). The 
summary estimates, RR is 0.73 and the 95% CI does not include the value 1 (0.57 to 0.93). At the same 
time, the position of the diamond favours the intervention group as it does not touch or cross the line 
of no effect, which means the meta-analytic effect is statistically significant. The inference is that those 
who were exposed the intervention had a 27% (% decrease= (1-RR) x 100 = (1-0.73) x 100 = 27%) 
reduced risk of reoccurrence of apical periodontitis compared to the control. 
 
 
 
 
